It’s been a long road for Pfizer’s dacomitinib, but the targeted lung cancer drug final has an FDA green light.

Late Thursday, the agency handed Pfizer an OK for the cancer-fighter, which will bear the trade name Vizimpro. The approval clears the med, which will launch with a list price of $12,400 per month, to treat metastatic non-small cell lung cancer patients with one of two specific EGFR mutations.

The go-ahead comes more than a year after Pfizer trotted out positive phase 3 results for the drug at 2017’s American Society of Clinical Oncology (ASCO) annual meeting. Data showed that Vizimpro had beaten out an in-class rival, AstraZeneca’s Iressa, at delaying cancer growth in newly diagnosed patients, paring down the risk of progression or death by 41%.